circadian clock raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-18. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
A pathologists' assistant (PA or PathA) is a physician extender whose expertise lies in gross examination of surgical specimens as well as performing hospital, medicolegal, and forensic autopsies. Their education is analogous to physician assistants, consisting of a didactic and a clinical component and concluding in a master's degree. Certification of pathologists' assistants is through a board exam by the American Society for Clinical Pathology (ASCP). In the United States, the profession is represented by the American Association of Pathologists' Assistants (AAPA). Pathologists' Assistants in the United States are currently only required to be licensed in three states: Nevada, West Virginia, and New York. In most other states, the scope of PAs falls under CLIA high complexity testing which requires an associate degree.
Duramycin has completed phase II clinical trials for the treatment of cystic fibrosis. Other bioactive RiPPs include the antibiotics cyclothiazomycin and bottromycin, the ultra-narrow spectrum antibiotic plantazolicin, and the cytotoxin patellamide A. Streptolysin S, the toxic virulence factor of Streptococcus pyogenes, is also a RiPP. Thyroxine is an example of a mammalian RiPP due to its biosynthetic origin as thyroglobulin.
Natural opiates: alkaloids contained in the resin of the opium poppy, primarily morphine, codeine, and thebaine, but not papaverine and noscapine which have a different mechanism of action Esters of morphine opiates: slightly chemically altered but more natural than the semi-synthetics, as most are morphine prodrugs, diacetylmorphine (morphine diacetate; heroin), nicomorphine (morphine dinicotinate), dipropanoylmorphine (morphine dipropionate), acetylpropionylmorphine, dibenzoylmorphine, diacetyldihydromorphine; Semi-synthetic opioids: created from either the natural opiates or morphine esters, such as hydromorphone, hydrocodone, oxycodone, oxymorphone, ethylmorphine, buprenorphine and desomorphine; Fully synthetic opioids: such as fentanyl, pethidine, levorphanol, methadone, tramadol, tapentadol, and dextropropoxyphene; Endogenous opioid peptides, produced naturally in the body, such as endorphins, enkephalins, dynorphins, and endomorphins. Endogenous opioids, non-peptide: Morphine, and some other opioids, which are produced in small amounts in the body, are included in this category. Natural opioids, non-animal, non-opiate: the leaves from Mitragyna speciosa (kratom) contain a few naturally occurring opioids, active via Mu- and Delta receptors. Salvinorin A, found naturally in the Salvia divinorum plant, is a kappa-opioid receptor agonist. Tramadol and tapentadol, which act as monoamine uptake inhibitors also act as mild and potent agonists (respectively) of the μ-opioid receptor. Both drugs produce analgesia even when naloxone, an opioid antagonist, is administered.
=== Names === Estrogens, conjugated is the generic name of the drug and its USPTooltip United States Pharmacopeia and JANTooltip Japanese Accepted Name. It is also known as conjugated estrogens or as conjugated equine estrogens. The brand name Premarin is a contraction of "pregnant mares' urine". CEEs are marketed under a large number of brand names throughout the world. The major brand name of the natural form of CEEs manufactured from the urine of pregnant mares is Premarin. Major brand names of fully synthetic versions of CEEs include Cenestin and Enjuvia in the United States and C.E.S. and Congest in Canada. CEEs are also formulated in combination with progestins. Major brand names of CEEs in combination with medroxyprogesterone acetate include Prempro and Premphase in the United States, Premplus in Canada, Premique in the United Kingdom and Ireland, Premia in Australia and New Zealand, and Premelle in South Africa. Prempak-C is a combination of CEEs and norgestrel which is used in the United Kingdom and Ireland, and Prempak N is a combination of CEEs and medrogestone which is used in South Africa. Many of the aforementioned brand names are also used in other, non-English-speaking countries.
Sources: en.wikipedia.org
== Efficacy == IPT has not been proven to work. Lab research indicates that there is not even a theoretical possibility of it being an effective treatment for most cancers. Research over the decades has proved that most cancers grow when exposed to more insulin. One study of men with prostate cancer showed that survival was significantly shorter (11 months for men who received IPT vs 18.9 months for men on standard treatment). A second small trial showed that women with metastatic breast cancer were less likely to see short-term disease progression if they received IPT with low-dose methotrexate than if they received either insulin alone or low-dose methotrexate alone. (This study did not compare IPT against any of the proven multi-drug chemotherapy regimens.)
This suggests BDNF is not only capable of initiating synapse formation through its effects on NMDA receptor activity, but it can also support the regular every-day signaling necessary for stable memory function. BDNF is also required for stabilizing actin polymerization in spines through triggering the activation of the WAVE regulatory complex.
In an interview with Democracy Now!, Greg Grandin said that the strike was "bringing the logic of Gaza into the Caribbean, in terms of unaccountability, impunity and an expansive notion of national defense to justify what is, in effect, just extrajudicial killing." A former ICC chief prosecutor, Luis Moreno Ocampo, told the BBC that the strikes would be considered under international law as crimes against humanity. Referring to premeditated killing outside of armed conflict as murder, he also said: "For me, it's very clear. A crime against humanity is a systematic attack against a civilian population, and there is no clarity why these people are not civilians, even [though] they could be criminals ... and it's clearly systematic, because President Trump says they have planned and they organised this, so that should be the charge." The UN Human Rights Council released a report in September 2026 concluding that the killings were unjustified in national or personal self-defense and added "There are reasonable grounds to believe that the reported 68 attacks that killed 223 people constituted crimes against humanity of murder under customary international law.”
It is injected once a month, after the first month having a double dose. The main reported side effects are injection site reactions, although there are a growing number of reports of severe side effects from a minority of patients. Approved by the FDA in February 2020, ubrogepant (Ubrelvy) is an oral medication manufactured by AbbVie. Also approved that month, eptinezumab (Vyepti), is an intravenous migraine prophylactic medication manufactured by Lundbeck. Rimegepant (Nurtec ODT) subsequently became the first oral CGRP receptor antagonist to be approved by the FDA for both acute migraine treatment (approved February 2020) and prevention of episodic migraine (approved June 2021). It is manufactured by Pfizer. In September 2021 the FDA approved Qulipta (atogepant), the first oral CGRP receptor antagonist approved to prevent chronic migraine. The phytocannabinoids delta-9 tetrahydrocannabinol (Δ9-THC) and its oxidative byproduct cannabinol (CBN) are found to induce a CB1 and CB2 cannabinoid receptor-independent release of calcitonin gene-related peptide from capsaicin-sensitive perivascular sensory nerves, an action that other psychotropic cannabinoids cannot do.
== Applications == Aerosol science and measurements field, especially aerosol mass spectrometry has grown a lot over the last couple decades. Its growth is partly due to the instruments versatility, it has the ability to analyze a particles size and chemical composition, and perform bulk and single-particle measurements. The versatility of aerosol mass spectrometers allow for them to be used for many different applications in both the lab and field. Over the years aerosols mass spectrometers have been used for anything from determining emissions sources, human exposure to pollutants, radiative transfer and cloud microphysics. Most of these studies have utilized the mobility of the AMS and has been fielded in urban, remote, rural, marine, and forested environments around the world. AMS have also been deployed in mobile platforms such as ships, mobile laboratories, and aircraft. One recent emission study in 2014 was performed by two NASA research aircraft, a DC-8 and a P-3B, that were outfitted with aerosol instrumentation (AMS). The aircraft were sent to perform analysis of atmospheric samples over the oil sands mining and upgrading facilities near Ft. McMurray, Alberta, Canada. The purpose of the study was to test the emission from the facilities, and determine if they match the requirements. The results of the study was that compared to estimates of annual forest fire emissions in Canada, the oil sands facilities are a minor source of aerosol number, aerosol mass, particulate organic matter, and black carbon.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.